MicroRNA Functionality in Cancer Biology

MicroRNAs (miRNAs) are small, non-coding RNA molecules of approximately 22 nucleotides that regulate gene expression post-transcriptionally by binding to complementary sequences within messenger RNA (mRNA) targets. In the context of cancer biology, miRNAs orchestrate key processes including cell proliferation, apoptosis, differentiation and metastasis. Dysregulated miRNA expression can act as either oncogenic drivers or tumour suppressors, depending on the cellular context and the repertoire of their mRNA targets.

The emerging landscape of miRNA functionality reveals their capacity to modulate entire gene networks rather than single targets. This network-based regulation underpins critical hallmarks of malignancy, such as evasion of programmed cell death, sustained proliferative signalling and enhanced migratory potential. Aberrant miRNA expression profiles are consistently observed across diverse tumour types, offering both mechanistic insight and prospective biomarkers for diagnosis, prognosis and therapeutic stratification.

Beyond their endogenous roles, synthetic miRNA mimics and antagonists have advanced into preclinical development. Antagonists of oncogenic miRNAs can relieve repression of tumour suppressor genes, whereas exogenous mimics of downregulated miRNAs can restore control over proliferative or invasive pathways. Challenges remain in achieving efficient and cell-type specific delivery, minimising off-target effects and deciphering the dual roles of certain miRNAs in immune modulation versus tumourigenesis.

Overall, the functional versatility of miRNAs in cancer biology offers a unifying framework to understand tumour heterogeneity, to refine molecular classification and to design innovative RNA-based interventions that complement existing chemotherapeutic and immunotherapeutic regimens.

Research from Nature Portfolio

An integrated analysis of independent hepatocellular carcinoma datasets has yielded a comprehensive miRNA expression database. By consolidating RNA-sequencing and microarray profiles, researchers validated over one hundred prognostic miRNA candidates, uncovering specific miRNAs whose expression correlates strongly with patient survival. This work established a robust platform for independent validation of candidate biomarkers, identified key miRNAs whose dysregulation distinguishes tumour from normal tissue and highlighted several miRNAs as potential targets for prognostic panels in liver cancer management.

MicroRNA Functionality in Cancer Biology publication trend

The graph below shows the total number of articles in microrna functionality in cancer biology across all publications each year (not limited to Nature Index journals).

Technical terms

microRNA (miRNA): Short non-coding RNA that regulates gene expression by base pairing with target mRNAs.

3′-untranslated region (3′-UTR): Non-coding segment at the end of mRNA where miRNAs commonly bind to regulate stability or translation.

Progression-free survival (PFS): Interval during which a patient’s disease does not worsen following treatment.

Extracellular vesicles (EVs): Membrane-bound particles secreted by cells containing proteins, lipids and nucleic acids, including miRNAs.

Xenograft model: Experimental system in which human tumour cells are implanted into immunocompromised animals to study cancer biology and therapeutics.

References

1. Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer. Molecular Cancer (2024).
2. Discovery of novel microRNA mimic repressors of ribosome biogenesis. Nucleic Acids Research (2024).
3. Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study. Journal of Experimental & Clinical Cancer Research (2024).
4. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Scientific Reports (2018).